SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The ticket is $Testicle. EVERY SINGLE ONE OF YOU CAME FROM A $Testicle. $Testicle always bounce.   We have a website on which you can create art or memes. We have a community. We have a raid group. We aim to provide the best testicular care on CT.   We might even have to call on our nefarious leader, Harry Bolz. Alright Chad, SACK TF. Or else you’re a Low T beta male.   If you have questions and or concerns please feel to reach out to a team member on how you can acquire or become a high testosterone male in a sea of betas. I mean how else does one live if not as a High T male?

Testicle

The cryptocurrency "Testicle" is rapidly trending due to its outrageous and highly debated name, sparking widespread disbelief and amusement across the community. Conversations are dominated by curiosity about its existence and how to acquire it, alongside strong opinions labeling it a "shetcoin" or "garbage," yet some are making significant investments with bold claims. This phenomenon highlights the speculative and often satirical nature of certain digital assets, with users debating its serious investment potential.

USELESS

USELESS CRYPTO is trending as its ironic name resonates with a community bullish on its speculative potential in the meme coin sector. The coin is gaining significant attention due to recent prominent exchange listings and visible accumulation by major crypto whales, fueling expectations of a substantial parabolic run. Many community members are projecting multi-billion dollar market caps, drawing parallels to past meme coin surges despite its explicit "useless" branding.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is actively discussed as a value opportunity, fueled by the recent appointment of CEO Steve Cahillane and the planned separation into two independent companies by 2026. While many investors are drawn to its attractive dividend and perceived "covid pricing" as a defensive play amid market rotation, skepticism persists regarding revenue challenges and claims of market manipulation by institutional analysts. The community is sharply divided on whether the impending split will truly unlock significant shareholder value.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is trending due to strong viral game engagement, notably with "Escape Tsunami For Brainrots!", which has fueled analyst upgrades and sparked discussions of a technical "breakout" for the stock. However, community sentiment is divided, with many debating the platform's long-term profitability and navigating recent controversies surrounding user safety, moderation changes, and increased regulatory scrutiny.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending due to recent positive 18-month functional data for its Duchenne gene therapy, RGX-202, showing durable treatment effects, alongside anticipation for an FDA decision on RGX-121 for Hunter Syndrome, which has received Priority Review. The community is actively discussing the strength of the company's pipeline in gene therapy, especially its comparative profile to competitors in Duchenne and its perceived undervaluation. Bolstered by new non-dilutive financing and strategic partnerships, investors are focused on these upcoming regulatory and clinical milestones.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy is trending following the introduction of its high-density Indensity battery storage system, keenly watched by investors for its potential in critical infrastructure, especially for AI data centers. This innovation, coupled with increasing demand for its zinc-based solutions and broader tailwinds for domestic energy storage, is fueling widespread bullish sentiment and discussions around significant growth prospects.

Vanguard Group, Inc. - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF ($VTI) is actively discussed as investors weigh its broad market diversification against the outperformance of growth-focused funds like $QQQ during recent market strength. Community conversation centers on $VTI's role as a "painfully simple, yet effective" long-term core holding amid broader debates on market highs and the sustainability of concentrated tech gains, with some considering diversification into international markets.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos (XTZ) is trending following positive developments for its Etherlink L2, including a "Uranium Tokenization Breakthrough" and surging transaction growth, solidifying its Real World Asset (RWA) narrative. While supporters highlight its staking appeal and potential for further adoption, a vocal segment of the community remains skeptical, citing concerns about its token supply. The discourse positions XTZ as a key player amidst broader anticipation for an "Alt Coin Season."

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is generating considerable buzz as its Shibarium network reports a significant increase in new addresses, leading to community speculation about an upcoming surge in transaction activity. Enthusiasts express strong confidence and hope for substantial "altseason" gains, though some participants remain wary, questioning its utility and comparing it unfavorably to newer meme tokens.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue is trending amidst a definitive acquisition bid from Kimberly-Clark, poised to create a larger consumer health powerhouse. Community sentiment is divided, with some investors seeing compelling value and a strategic merger, while others remain cautious due to the stock-heavy deal structure and ongoing legal concerns regarding its product portfolio, particularly Tylenol and talc.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Scienture has commenced selling Arbli, the first FDA-approved ready-to-use liquid losartan formulation.</li><li>The U.S. losartan market is worth about $256 million annually, offering strong growth potential for Arbli.</li><li>Scienture secured key GPO agreements to expand Arbli’s availability to over 2,500 healthcare facilities nationwide.</li></ul>Scienture Holdings Inc. (SCNX) on Thursday announced the launch of commercial sales for its new product, Arbli (losartan potassium) Oral Suspension, 10 mg/mL.Arbli is the first FDA-approved, ready-to-use oral suspension of losartan potassium, offering patients who require alternatives to pills a safe and consistent treatment option.&nbsp;With the U.S. losartan market generating around $256 million annually and more than 71 million prescriptions written each year, according to IQVIA data, Scienture sees a strong potential for this new product.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of Scienture Holdings surged by more than 122% by Thursday noon. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<figure class="image"><img style="aspect-ratio:938/107;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_23_114143_png_e27a7261e9.webp" alt="SCNX’s Sentiment Meter and Message Volume as of 11:25 a.m. ET on Oct. 23, 2025 | Source: Stocktwits" width="938" height="107"><figcaption>SCNX’s Sentiment Meter and Message Volume as of 11:25 a.m. ET on Oct. 23, 2025 | Source: Stocktwits</figcaption></figure>A bullish Stocktwits user said the company’s valuation might reach billions if the product is expanded globally.&nbsp;<stembedurl>https://stocktwits.com/jreddyN/message/633437362</stembedurl><h2 class="st-heading-2">Arbli’s Importance</h2>Arbli is a unique liquid form of losartan, a common medication for high blood pressure. It doesn’t need compounding, offers a smaller dosing volume, and has a long shelf life at room temperature. Arbli is approved to treat hypertension in patients over six years old, to lower stroke risk in those with hypertension and heart enlargement, and manage diabetic kidney disease in certain type 2 diabetes patients.To support Arbli’s market entry, Scienture has secured Pharmacy Benefit Manager-led Group Purchasing Organization (PBM-Led GPO) agreements to broaden commercial coverage and formulary inclusion. Scienture has also finalized contracts with multiple commercial GPOs, allowing Arbli to reach over 2,500 healthcare institutions nationwide.&nbsp;Scienture’s stock has lost over 79% in 2025 and over 82% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/datavault-ai-to-boost-growth-with-new-headquarters-quantum-centers/cLG4mQdR3rQ">Datavault AI To Boost Growth With New Headquarters, Quantum Centers</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is Scienture Stock Rising Today?

Scienture has commenced selling Arbli, the first FDA-approved ready-to-use liquid losartan formulation.

Equity

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Commack, NY.

SCNX
Scienture Holdings Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest SCNX News

SCNXScienture Holdings Inc.